Wilson’s Disease Market Report and Forecast 2024-2032

Wilson’s Disease Market Outlook

The Wilson’s disease market size was valued at USD 1457.5 million in 2023, driven by the rising research and development activities in drug development across the major markets. The market is expected to grow at a CAGR of 3.2% during the forecast period of 2024-2032, with the values likely to rise from USD 1498.9 million in 2024 to USD 1926.6 million by 2032.

Wilson’s Disease: Introduction

Wilson’s disease is a rare genetic condition that leads to copper level build up in several body organs, particularly, brain, eyes, and liver. Major symptoms include yellowing of skin and eyes, occurrence of golden-brown or copper-colored rings around the irises of the eyes (Kayser-Fleischer rings), along with tiredness, loss of appetite, fluid buildup in legs and stomach area. It is treated via medications and surgery in case of extreme cases.

Wilson’s Disease Market Analysis

Wilson’s disease has been treated via medications that constitute chelating agents (medicines that remove copper from the body). Penicillamine (Cupramine, Depen) and trientine (Syprine) are two commonly prescribed medications that help remove excess copper from the body. Zinc is another frequent medication that blocks copper absorption in intestines.

Wilson’s disease market demand is further fueled by the rising advancements in gene therapies. In September 2023, UC Davis Health researchers infused the first ever gene therapy in an affected patient. The clinical trial for Wilson’s disease called CYPRUS2+ displayed positive results for UX701, the investigational gene therapy treatment. It is an adeno-associated virus gene therapy that restores the function of ATP7B, that improves copper metabolism and distribution in the body.

With increasing technical advances in the medical ecosystem, scientists have been looking into finding ways to effectively devise better diagnostic methods that identify the illness at an early stage. Similarly, a better understanding of human physiology, along with hefty investments made by public and private institutions, is also poised to fuel the Wilson’s disease market value in upcoming years.

Wilson’s Disease Market Segmentation

Market Breakup by Diagnosis Method

• Blood and Urine Test

• Eye Exam

• Biopsy

• Genetic Testing

Market Breakup by Treatment Type

• Medications
  • Penicillamine
  • Trientine Dihydrocholoride
  • Trientine Tetrahydrochoride

• Surgery

Market Breakup by Mode of Administration

• Injectable

• Oral

• Others

Market Breakup by End User

• Hospitals

• Homecare

• Specialty Clinics

• Others

Market Breakup by Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

Wilson’s Disease Market Overview

The United States is anticipated to dominate the Wilson’s disease market share in the forecast period. The market size can be accredited to increasing mergers and acquisitions in the region to foster better inventions for patient outcomes. Several companies are growing their product portfolios to meet the high demand for patient therapeutics.

Europe is another significant market with a robust healthcare and research infrastructure that aids market growth. The presence of prominent research and academic institutions along with leading healthcare companies also fuels market value.

Wilson’s Disease Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Teva Pharmaceutical

• ANI Pharmaceuticals

• Bausch Health

• DR. REDDY’S LABORATORIES LTD

• Breckenridge Pharmaceutical, Inc.

• Par pharmaceutical

• Lupin

• Panacea Biotech Ltd

• Apotex

• Navinta LLC

• Amneal Pharmaceuticals LLC.

• Meda Pharmaceuticals

• Ipsen Pharma

• Noblepharma Co., Ltd.

• Wilson Therapeutics AB

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report